KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$118.18
+0.76%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 353.76x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.51x
- Price / sales
- 93.60x
- Price / cash flow
- -41.50x
Enterprise value
- Enterprise value
- $9.2B
- EV / sales
- 87.80x
- EV / EBITDA
- -31.49x
- EV / EBIT
- -26.32x
- Market cap
- $9.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026